NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis

Teva Pharmaceutical Industries Limited (TEVA) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

TEVA

$40.62

−$0.23 (−0.56%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TEVA with… →

TEVA Key Statistics

As of Oct 21, 2026
Trading
Open
$40.18
Previous Close
$40.85
Day's Range
39.50–41.09
52-Week Range
18.83–42.02
Volume
4.59M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.82
Valuation
Market Cap
$47.37B
P/E Ratio
67.70
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.17
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.71
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.74
EPS (ttm)Profit attributable to each share over the last twelve months.
0.60
Financials (FY)
Revenue (FY)
$17.26B+4.31%
Net Income (FY)
$1.41B
Profit marginThe share of revenue left as profit after all costs and taxes.
4.08%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.17B
1-Year Return
+113.90%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
5.70M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TEVA closed at $40.62, +113.90% over 1 year.

Teva Pharmaceutical Industries Limited (TEVA) has a market capitalization of $47.37B.

In fiscal 2025, TEVA reported revenue of $17.26B.

TEVA Stock Return by Calendar Year

Teva Pharmaceutical Industries Limited (TEVA) 10-year return: what $10,000 became

1 year
$10,000 $21,390
+113.90%
5 years
$10,000 $40,059
+300.59%
10 years
$10,000 $9,631
−3.69%

If you had invested $10,000 in Teva Pharmaceutical Industries Limited (TEVA) 10 years ago, at the close on October 21, 2016, it would have been worth $9,631 at the close on October 21, 2026: −3.69% in total, −0.38% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+30.15%
2025+41.61%
2024+111.11%
2023+14.47%
2022+13.86%
2021−16.99%
2020−1.53%
2019−36.45%
2018−18.63%
2017−45.96%
2016 (partial year)−30.86%

As of October 21, 2026.

TEVA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$17.26B$1.41B8.2%
2024$16.54B−$1.64B−9.9%
2023$15.85B−$559.00M−3.5%
2022$14.93B−$2.45B−16.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$17.26B$8.94B$3.95B$1.41B8.2%
2024$16.54B$8.06B$3.36B−$1.64B−9.9%
2023$15.85B$7.65B$3.19B−$559.00M−3.5%
2022$14.93B$6.97B$2.69B−$2.45B−16.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TEVA Dividend History

$0.85+150.0% vs 2016

Dividends per share, 2017 · 4 payments

YearDividends per sharePaymentsChange
2017$0.854+150.0%
2016$0.341—

Most recent payment: $0.21 per share, ex-dividend November 27, 2017. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

TEVA Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricTEVADrug Manufacturers - Specialty & Generic medianvs median
P/E67.7020.313.3x the median
P/S ratio2.742.1030% above
Profit margin4.08%−8.14%12.2 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Teva Pharmaceutical Industries Limited (TEVA) at $47.37B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 31,173.

Over the past 52 weeks the price has ranged from $18.83 to $42.02. The most recent close on file for TEVA is $40.62, dated October 21, 2026. That is −$0.23 (−0.56%) against the previous close. The latest close sits 115.72% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $17.26B. Against the prior fiscal year total of $16.54B, that is a change of +4.31%. Net income for the same year was $1.41B. Profit margin runs at 4.08%. That is 12.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 0.6.

Across the 4 fiscal years on file, revenue moves from $14.93B in 2022 to $17.26B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

TEVA trades at a trailing price-to-earnings ratio of 67.7. That is 3.3 times the Drug Manufacturers - Specialty & Generic median of 20.31. The forward P/E on file is 13.17. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.71. The price-to-sales ratio is 2.74. On price-to-sales that is 30.29% above the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.82. Daily returns over the trailing 10 years annualize to a volatility of 47.58%. Over the trailing twelve months the total return is +113.90%. Measured over 10 years, that is −0.38% a year compounded.

Growth & Income

The dividend record for TEVA runs through 2017. Dividends are recorded for 2 calendar years; 2017 shows 4 payments totalling $0.85 a share. The year before, 2016, totalled $0.34 a share.

2026 is still running; the total return is +30.15% year to date. The strongest complete calendar year on file is 2024 at +111.11%; the weakest is 2017 at −45.96%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Teva Pharmaceutical Industries Limited (TEVA) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Takeda Pharmaceutical Company Limited TAK $63.67B —
Haleon plc HLN $44.06B 20.5
Zoetis Inc. ZTS $32.90B 13.1

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Teva Pharmaceutical Industries Limited trades at a P/E of 67.7.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B

 NBIX

Neurocrine Biosciences, Inc.

$14.36B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Visit website →